Xpression microarray test for the subclassification of leukemia. Roche Molecular Systems
Xpression microarray test for the subclassification of leukemia. Roche Molecular Systems, Inc. has business relationships with Qiagen and is currently validating Qiagen products for the AmpliChip Leukemia Test.Authors’ contributionsMCDO performed the microarray experiments and wrote the paper, LT contributed to perform the experiments, AZ, RL, and WML analyzed the microarray data, GB recorded clinical data, GK supervised the study and get BX795 writing of the manuscript, and AK provided the original concept of the study, and contributed to writing the paper.Page 13 of(page number not for citation purposes)BMC Genomics 2007, 8:http://www.biomedcentral.com/1471-2164/8/Additional material7.Additional FileSupplementary Data. This file contains supplementary figures with additional comments explaining details of analysis, results, and interpretation. Click here for file [http://www.biomedcentral.com/content/supplementary/14712164-8-188-S1.doc]8.Additional FileThis Excel file contains further details about each total RNA isolation method, including cRNA quality and quantity values as well as microarray quality and quantity values for each experiment. Click here for file [http://www.biomedcentral.com/content/supplementary/14712164-8-188-S2.xls]9.10.Additional FileThis Excel file contains details about each total RNA isolation method and leukemia classification details for each CEL file. All microarray raw data (*.cel files) are available online through the Gene Expression Omnibus database with the series accession number GSE7757. Click here for file [http://www.biomedcentral.com/content/supplementary/14712164-8-188-S3.xls]11.12.AcknowledgementsSupported in part by Fondazione Citt?della Speranza, CNR, MURST ex 40 and 60 and Roche Molecular Systems, Inc., Pleasanton, CA, USA. The authors would like to thank the European LeukemiaNet gene expression profiling working group members Torsten Haferlach, Ken Mills, and Amanda Gilkes for helpful comments and critical reading of the manuscript.
Rashid and Sultana Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P69 http://www.immunotherapyofcancer.org/content/3/S2/PPOSTER PRESENTATIONOpen AccessModulation PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/26437915 of chemically induced renal carcinogenesis by Chrysin via inhibition of oxidative stress, hyper-proliferation and inflammation at preclinical stageSummya Rashid*, Sarwat Sultana From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 NovemberAcknowledgments The authors are thankful to UGC, New Delhi India under SAP for Departmental Research Support II and BSR for the award of project to carry out the study. Published: 4 NovemberThe present study was planned to investigate the chemopreventive efficacy of Chrysin (CH) against renal carcinogenesis in Wistar rats. Ferric nitrilotriacetate (Fe-NTA) is a potent nephrotoxicant and known renal carcinogen. CH is a natural flavonoid found in honey, propolis, blue passion flower. In vitro data suggests that it has anti-oxidative, anti-inflammatory, anti-apoptotic properties. Renal carcinogenesis is a multistep process and it originates from a series of molecular and histopathological alterations. Renal cancer was initiated by single intraperitoneal injection of N-nitrosodiethylamine and promoted chronically by twice weekly administration of Fe-NTA for 16 weeks and rats were sacrificed after 24 weeks. CH was administered at two doses daily. The possible mechanism could be induction of oxidativ.